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daily living limitations, supplemental insurance coverage and
region. We also examined whether prescription drug coverage
modiﬁed the difference in expenditures among enrollees with
asthma. RESULTS: Medicare beneﬁciaries with asthma had
higher mean Part A expenditures ($4412 versus $2744), longer
average hospital stays (3.53 days versus 1.82), and higher 
Part B expenditures ($3688 versus $2547) than those without
asthma. In regression analysis, asthma increased mean Part A
expenditures by $850 and Part B expenditures by $551. Outpa-
tient prescription drug coverage decreased Part B spending on
persons with asthma by $446, but increased Part B spending by
$243 for those without asthma. Prescription drug coverage had
no effect on either Part A expenditures or the number of days
spent in the hospital for either those with or those without
asthma. CONCLUSIONS: Asthma increases expenditures in the
Medicare program, but the increase is moderated by outpatient
prescription drug coverage. This suggests that spending increases
associated with the new Medicare prescription drug beneﬁt may
be mitigated by reductions in spending on chronic illnesses such
as asthma. As the new drug beneﬁt is designed, attention should
be focused on the identiﬁcation of medications that reduce
overall Medicare spending to insure that they are covered by
drug plans.
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OBJECTIVE: To estimate the annual excess cost of chronic
obstructive pulmonary disease (COPD) to a large managed-care
plan. METHODS: This study employed a retrospective, matched
cohort design and administrative claims data from the large
multi-state managed care database. Patients selected were 35+
years of age, with a diagnosis of COPD in 2001, and eligible for
medical and pharmacy beneﬁts as of January 1, 2001. The com-
parison cohort consisted of patients without COPD matched on
age, gender, geographic region, and insurance coverage type. The
excess cost of COPD was estimated as the difference in mean
health plan payments between the COPD and comparison
cohorts during 2001. Multivariate techniques were employed to
assess the contribution of mortality and comorbidity to excess
costs. RESULTS: A total of 61,527 patients with COPD met
study inclusion criteria, a prevalence of approximately 9%.
Approximately 12% were diagnosed with emphysema, 25%
with chronic bronchitis, and 63% with unclassiﬁed chronic
airway obstruction. COPD patients and their matched controls
(n = 61,527) averaged 71 years of age and 50% were female.
Charlson comorbidities, especially vascular disease and cancer,
were more common in the COPD cohort. The utilization of most
types of services was signiﬁcantly (P < 0.001) higher in the COPD
group, including hospitalizations (43% vs. 14%), emergency
room visits (47% vs. 21%), and home health-care services (28%
vs. 8%). The annual per-patient excess cost of COPD from the
health plan perspective was estimated to be approximately
$7900 ($11,350 for the COPD cohort minus $3450 for the
control cohort), 58% of which was due to hospitalizations. The
higher burden of comorbidity and mortality in the COPD cohort
accounted for about 40% of the observed difference in excess
costs. CONCLUSIONS: The excess cost of COPD is substantial.
Acute hospitalizations and greater comorbidity burden explain
a large portion of these excess costs.
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OBJECTIVE: Recent guidelines have recommended that children
aged 6–24 months should be immunized with inﬂuenza vaccine
to protect against inﬂuenza. Our objective was to evaluate health
outcomes and costs to society of inﬂuenza vaccination on
inﬂuenza and acute otitis media infection in an otherwise healthy
population of 6–24 month old infants. METHODS: Based 
on published and unpublished data, a decision analytical model
comparing two strategies: children vaccinated with inactivated
inﬂuenza vaccine and children not vaccinated children has been
developed. The clinical pathway predicted the probability of
becoming infected with inﬂuenza, developing acute otitis media
in conjunction with inﬂuenza or alone. Health outcomes used in
this model included days of illness as well as days of paid
employment missed by primary caregiver. Costs incorporated
into the model included both direct and indirect costs including
cost of vaccination, pharmaceutical costs of treatment of infec-
tion, hospitalization, and caregiver employment income lost.
Robustness of results was tested by univariate and multivariate
sensitivity analysis. The model was used to simulate the results
for an otherwise health population comparing vaccination to
non-vaccination strategy of care. RESULTS: Vaccination pro-
grams had lower cost and better health outcomes when com-
pared to non-vaccination programs. Vaccinated children had an
expected cost to society of $329.51 with 2.29 expected days of
illness and 1.93 days of work missed by the primary caregiver.
Non-vaccinated children had an expected cost of $393.78 with
3.97 expected days of illness and 2.63 days of work missed by
the primary caregiver. Univariate and multivariate sensitivity
analysis showed these results to be robust in upholding vaccina-
tion as a cost effective alternative to no vaccination over a wide
range of assumptions. CONCLUSION: Immunization with inac-
tivated inﬂuenza vaccine is a cost effective treatment in reducing
the incidence of both inﬂuenza and acute otitis media for chil-
dren aged 6–24 months.
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OBJECTIVE: This study evaluates the projected cost-
effectiveness of antiviral treatments (amantadine or oseltamivir)
with and without the use of inﬂuenza rapid tests in children.
METHODS: A decision tree was developed to predict costs and
health effects of 5 strategies: no antiviral treatment, empirical
treatment with amantadine, empirical treatment with
oseltamivir, testing then treatment with amantadine, and testing
then treatment with oseltamivir. The target population was strat-
iﬁed by age (6–23mos, 2yrs, 3–4yrs, 5–11yrs, and 12–17yrs)
and risk status (high or low risk for inﬂuenza-related complica-
tions). Probabilities and costs (direct and opportunity) for
uncomplicated inﬂuenza, inﬂuenza-like illness, outpatient visits,
hospitalizations, deaths, effectiveness of antiviral treatments,
treatment adverse events, and characteristics of inﬂuenza rapid
tests were based on primary and secondary data. Quality adjust-
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ments (time-tradeoff amounts) for inﬂuenza-related events were
based on primary data from a telephone survey (n = 112). Incre-
mental cost-effectiveness ratios in dollars per quality-adjusted
life year (QALY) were calculated. RESULTS: For an unvacci-
nated population, the base case cost per QALY for empirical
treatment with amantadine was less than $1000 for all sub-
groups and for empirical treatment with oseltamivir ranged from
less than $1000 to $8000 depending on age and risk status.
Results were sensitive to inﬂuenza illness rate, proportion of
inﬂuenza-like illness that is conﬁrmed inﬂuenza, and inﬂuenza
vaccination status. Testing and treatment options were more
costly and less effective than empirical treatment options. Prob-
abilistic sensitivity analysis suggests that empirical treatment
with amantadine has similar cost-effectiveness ratios under many
scenarios while the cost-effectiveness ratios of empirical treat-
ment with oseltamivir show wider variability. CONCLUSIONS:
Empirical treatment with amantadine during peak inﬂuenza
season is notably more cost-effective than empirical treatment
with oseltamivir. Both reductions in test prices and improvement
in accuracy of rapid inﬂuenza tests will be needed to make testing
and treatment strategies attractive alternatives.
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OBJECTIVE: This study was designed to assess the cost-
effectiveness of cyclooxygenase-2 speciﬁc (COX-2) inhibitors
(rofecoxib and celecoxib) over non-selective non-steroidal anti-
inﬂammatory drugs (NSAIDs) in high-risk arthritis patients from
the perspective of the Veterans Health Administration (VA).
METHODS: This literature-based economic analysis compared
rofecoxib and celecoxib to NSAIDS in two arthritis patient pop-
ulations considered at higher risk of developing clinically signif-
icant upper gastrointestinal events (CSUGIEs): 1) patients of any
age with previous medical history of perforation/ulcer/bleed
(PUB), and 2) patients 65 years and older (regardless of history
of PUB). Two outcomes measures were reported 1) incremental
cost per CSUGIE averted over 1 year, and 2) incremental cost
per quality-adjusted life-year (QALY) gained, considering both
the mortality and morbidity associated with gastrointestinal
(including CSUGIEs) and cardiovascular-related adverse events.
When possible, costs were modeled to reﬂect the VA perspective.
Sensitivity analyses were conducted to test the robustness of the
analysis. RESULTS: Compared to NSAIDS, rofecoxib and cele-
coxib increased costs but reduced the incidence of CSUGIE. Cost
per CSUGIE avoided were $7,476 and $16,379 (in patients with
a PUB history) and $14,294 and $18,376 (in patients aged > 65
years) for celecoxib and rofecoxib, respectively. In both popula-
tions, celecoxib was associated with a cost per QALY less than
$50,000. In contrast, rofecoxib was found to cost more and
result in a net QALYs loss, due in particular to the increase in
the risk of cardiovascular complications, and was therefore con-
sidered cost-ineffective. Results were most dependent on assump-
tions about the incidence of cardiovascular events and CSUGIE
and the COX-2 inhibitors acquisition price. CONCLUSIONS:
This analysis suggests that the COX-2 inhibitors may be cost-
effective from the perspective of the VA. However, cost-
effectiveness appears to depend less on the speciﬁc characteris-
tics of the high-risk target population considered but more on
the agent evaluated.
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OBJECTIVE: The present study compared the cost-effectiveness
of four biologics—adalimumab, anakinra, etanercept, and inﬂix-
imab—used in the treatment of rheumatoid arthritis (RA).
METHODS: A decision analytic model was constructed to esti-
mate the costs and effectiveness of these biologics used alone or
in combination with methotrexate (MTX) during one year, from
the perspective of a managed-care organization. Direct costs 
consisted of drugs and health care resources. Effectiveness was
measured by Quality-Adjusted Life Years (QALYs) based on
preference weights and health states in which patients achieved
one of four levels of response according to the American College
of Rheumatology (ACR) response criteria (No ACR 20, ACR20,
ACR50, ACR70) and had one of the four levels of adverse effects
(no, mild, moderate, severe) due to their treatments. Drug costs
were US average wholesale price. Costs for health care resources
were those published by the Committee of Medicare and Med-
icaid Services and in the MEDSTAT DRG Guide. Preference
weights were obtained from a survey on patients with RA in
which visual analogue scale technique was used. Probabilities of
health states were derived from published clinical trial reports.
One-way sensitivity analyses were conducted on all variables to
test for robustness of the model. RESULTS: Among monother-
apies, the incremental cost-effectiveness ratio (ICER) of etaner-
cept compared to anakinra (the lowest cost option) was $13,387
per additional QALY, while etanercept dominated adalimumab.
Among combination therapies, the ICER of etanercept + MTX
compared to anakinra + MTX was $7925 per additional QALY.
Etanercept combination therapy dominated adalimumab and
inﬂiximab combination therapies. However, the costs of etaner-
cept + MTX and adalimumab + MTX were almost equal. Results
were sensitive to changes in treatment costs and probabilities of
health states in directions as predicted. CONCLUSIONS: For
monotherapy and combination therapy regimens, anakinra was
the least expensive option while etanercept dominated other
treatments.
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OBJECTIVE: This study reassessed the psychometric character-
istics of the original 33-item CSHQ-RA instrument using a rep-
resentative population of RA patients from 55 sites across the
US. METHODS: Three hundred seven of 309 screened patients
from a 24-week multicenter, open-label, single arm study of RA
patients receiving anakinra completed the 33-item CSHQ-RA,
the Medical Outcomes Study Short Form-36 (MOS SF-36) 
and the Stanford Health Assessment Questionnaire (HAQ) 
